NCT01467024Unknown不适用
Evaluation of the MP Diagnostics HTLV Blot 2.4
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 600
- 试验地点
- 2
研究概览
简要总结
The purpose of this study is:
- To assess the validity and reproducibility of the MP Diagnostics HTLV Blot 2.4.
- To conduct a sensitivity analysis of the HTLV Blot 2.4 using a known positive population.
详细描述
This is a retrospective study designed to assess the validity and reproducibility of the MP Diagnostics IVD device, the HTLV Blot 2.4 (MP Blot), in various populations. The study will be conducted at three geographical distinct locations.
The validity of the MP Blot will be assessed by calculating the following:
- Percent negative agreement with CDPHL Algorithm on 200 EIA negative specimens
- Percent positive agreement with CDPHL Algorithm on 200 EIA repeat reactive specimens
The sensitivity of the MP Blot will be evaluated by testing 200 known positive specimens. The study will be performed using three product lots at three clinical sites.
The reproducibility of the MP Blot will be assessed by testing two replicates of a three member panel at three clinical testing sites with each of three lots of product over multiple days by three operators.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •EIA Negative Population
- •Male or female
- •Completion of a health history evaluation for routine donor screening
- •Willing and able to provide informed consent
- •Negative screening assay results for all ARC screening assays
- •EIA Repeat Reactive Population
- •Male or female
- •Completion of a health history evaluation for routine donor screening
- •Willing and able to provide informed consent
- •Previous RR result by bioMerieux ELISA, Abbott EIA, and / or Abbott ChLIA PRISM
- •Known Positive Population
- •Male or female
- •Willing and able to provide informed consent
- •Previous reactive screening test using either the bioMerieux ELISA, the Abbott EIA or the Abbott ChLIA PRISM, followed by supplemental testing
排除标准
- •EIA Negative Population
- •Inadequate sample volume for testing
- •Unable to provide samples that meet the sample suitability requirements for testing
- •Positive screening result for any infectious disease tested by ARC
- •EIA Repeat Reactive Population
- •Inadequate sample volume for testing
- •Unable to provide samples that meet the sample suitability requirements for testing
- •Positive result for HIV, HBV, HCV, or any other infectious disease
- •Known Positive Population
- •Unwilling or unable to provide informed consent
- •Unable to provide adequate sample volume for testing
- •Unable to provide samples that meet the sample suitability requirements for testing
- •Positive result for HIV
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Dual Algorithm Post Market Clinical StudyHTLV-I InfectionsHTLV-II InfectionsHuman T-lymphotropic Virus 1Human T-lymphotropic Virus 2HTLV I Associated T Cell Leukemia LymphomaHTLV I Associated MyelopathiesNCT03146013MP Biomedicals, LLC100
Unknown
不适用
Clinical Validation of a Molecular Signature to Detect Cancer in Thyroid Nodules With Indeterminate CytologyThyroid NoduleThyroid CancerNCT02225509Diaxonhit1,000
Unknown
不适用
Place of the Hevylite Test in the Evaluation of MRD in MyelomaMyelomaNCT03702088University Hospital, Montpellier124
已完成
不适用
Feature Detection Study for Validation of Hamamatsu NanoZoomer S360MD Digital Slide Scanner SystemPathologyNCT03992768Hamamatsu Photonics K.K.540
撤回
不适用
Diagnostic Performance of 3T MRI T2 Mapping Technique in Chondro-labral Pathology of the Hip, Correlated With Intraoperative Arthroscopic Findings: Interventional Diagnostic Technique Validation Study (HPI MRI 3T)Hip Injuries and DisordersHip ArthrosisNCT06067243Istituto Ortopedico Rizzoli